HLE Glascoat Ltd: 575 Cr Order Book, 61 P/E – Chemical Equipment or Chemical Romance?
Date of Publishing -
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
1. At a Glance
HLE Glascoat Ltd is the “industrial Tinder” of pharma & chemical equipment — swiping right on filtration, drying, and glass-lined kit manufacturing. At ₹507/share (Aug 21 close), the market cap is a spicy ₹3,460 crore, trading at 61× earnings, which is like paying Oberoi prices for roadside chai. Their order book is a juicy ₹575 crore, profit doubled in FY25, and yet debt has also piled up (₹381 crore). Basically: gym body with credit card EMI.
2. Introduction
Imagine running an NBFC, boring. Imagine running a cement company, dusty. But running a company that makes the reactors and dryers for pharma and specialty chem players? Sexy. Because when Bharat is the “pharmacy of the world,” someone has to sell the lab ka dabba. That’s where HLE Glascoat comes in.
They are market leaders in filtration & drying (50%+ share), 2nd biggest in glass-lined reactors (25% share), and now also flirting with heat exchangers via Kinam Engineering. Their client list reads like a BSE A-list party — Bayer, UPL, Sun Pharma, Atul, BASF, Zydus, SRF, Dr. Reddy’s. Basically, all the folks who make the pills, sprays, and chemicals you’ve cursed about at chemists.
In short: a company that doesn’t sell drugs, but sells the drug makers their toys. The “picks & shovels” play of chemical gold rush.
3. Business Model (WTF Do They Even Do?)
Three strong verticals, each like a cricket batting lineup:
Filtration & Drying (~39% rev): The Virat Kohli of the portfolio. Absolute leader, >50% domestic market share. Customers can’t make APIs or specialty chems without these dryers. If you want it dry, HLE makes it.
Glass-Lined Equipment (~49% rev): The Rohit Sharma — second only to DDPS (world leader). Still 25% domestic share isn’t bad; makes reactors and vessels where chemists cook their “magic.”
Heat Exchangers (~12% rev): The Shubman Gill. Acquired Kinam Engineering (₹80 Cr) and got rights over 70% soon. Still a new vertical, but has global potential.
Clients spread across specialty chemicals (42%), pharma (39%), agrochems (9%), and others (10%). Which means when pharma sneezes, HLE catches a cold — but when pharma is in a bull run, HLE gets a buffet.
Question to readers: would you rather own a chemical company with pollution headaches, or the guys selling reactors and dryers with asset-light-ish glamour?
4. Financials Overview
Quarterly snapshot (Q1 FY26 vs Q1 FY25 vs Q4 FY25):
